Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type

D Auziņa; I Beinaroviča; B Janicka-Kupra; S Lejniece; A Lejnieks; V Groma

doi:10.32471/exp-oncology.2312-8852.vol-42-no-4.15289

Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type

D Auziņa (Corresponding Author), I Beinaroviča, B Janicka-Kupra, S Lejniece, A Lejnieks, V Groma

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

8 Downloads (Pure)

Abstract

BACKGROUND: Previous studies have pointed out the role of dickkopf-related protein 1 (DKK 1) - Wnt inhibitor, which is essential for osteoblast functioning, in the development of osteolytic lesions in multiple myeloma (MM).

AIM: To assess the DKK 1 expression displayed by myeloma cells in bone marrow trephine biopsies of patients with and without osteolytic lesions, and in different malignancy grades of the disease.

METHODS: The expression level of DKK 1 was assessed immunohistochemically in bone marrow of 49 MM patients presented with and without osteolytic lesions (the 1st and the 2nd group, respectively).

RESULTS: Levels of weak, moderate, and strong DKK 1 expression were distributed - as 43.33, 27.78 and 25.56%, and 63.91, 18.80, and 1.50%, respectively when evaluating the samples obtained from the 1st and the 2nd group. Statistically significant differences were found when the levels of DKK 1 expression in the 1st and the 2nd group were compared (χ2 = 51; df = 3; p < 0.001).

CONCLUSIONS: DKK 1 contributes to the development of osteolytic lesions in MM. The present study provides morphological evidence that inhibition in Wnt signaling may lead to bone damage observed in the advanced stage of the disease.

Original language	English
Pages (from-to)	285-288
Journal	Experimental Oncology
Volume	42
Issue number	4
DOIs	https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-4.15289
Publication status	Published - Dec 2020

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.32471/exp-oncology.2312-8852.vol-42-no-4.15289

Dickkopf-related protein 1 expressionFinal published version, 654 KB

https://exp-oncology.com.ua/wp/wp-content/uploads/2020/12/2728.pdf?upload=

Cite this

@article{25d87fb71239456594947cfd700cd848,

title = "Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type",

abstract = "BACKGROUND: Previous studies have pointed out the role of dickkopf-related protein 1 (DKK 1) - Wnt inhibitor, which is essential for osteoblast functioning, in the development of osteolytic lesions in multiple myeloma (MM).AIM: To assess the DKK 1 expression displayed by myeloma cells in bone marrow trephine biopsies of patients with and without osteolytic lesions, and in different malignancy grades of the disease.METHODS: The expression level of DKK 1 was assessed immunohistochemically in bone marrow of 49 MM patients presented with and without osteolytic lesions (the 1st and the 2nd group, respectively).RESULTS: Levels of weak, moderate, and strong DKK 1 expression were distributed - as 43.33, 27.78 and 25.56%, and 63.91, 18.80, and 1.50%, respectively when evaluating the samples obtained from the 1st and the 2nd group. Statistically significant differences were found when the levels of DKK 1 expression in the 1st and the 2nd group were compared (χ2 = 51; df = 3; p < 0.001).CONCLUSIONS: DKK 1 contributes to the development of osteolytic lesions in MM. The present study provides morphological evidence that inhibition in Wnt signaling may lead to bone damage observed in the advanced stage of the disease.",

author = "D Auziņa and I Beinarovi{\v c}a and B Janicka-Kupra and S Lejniece and A Lejnieks and V Groma",

note = "Autoru afiliācijas at{\v s}ķiras PDF versijā, {\v z}urnāla versijā, Pubmed un Web of Science datubāzēs.",

year = "2020",

month = dec,

doi = "10.32471/exp-oncology.2312-8852.vol-42-no-4.15289",

language = "English",

volume = "42",

pages = "285--288",

journal = "Experimental Oncology",

issn = "1812-9269",

publisher = "Morion LLC",

number = "4",

}

TY - JOUR

T1 - Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients

T2 - correlation with bone disease and plasma cell malignancy type

AU - Auziņa, D

AU - Beinaroviča, I

AU - Janicka-Kupra, B

AU - Lejniece, S

AU - Lejnieks, A

AU - Groma, V

N1 - Autoru afiliācijas atšķiras PDF versijā, žurnāla versijā, Pubmed un Web of Science datubāzēs.

PY - 2020/12

Y1 - 2020/12

N2 - BACKGROUND: Previous studies have pointed out the role of dickkopf-related protein 1 (DKK 1) - Wnt inhibitor, which is essential for osteoblast functioning, in the development of osteolytic lesions in multiple myeloma (MM).AIM: To assess the DKK 1 expression displayed by myeloma cells in bone marrow trephine biopsies of patients with and without osteolytic lesions, and in different malignancy grades of the disease.METHODS: The expression level of DKK 1 was assessed immunohistochemically in bone marrow of 49 MM patients presented with and without osteolytic lesions (the 1st and the 2nd group, respectively).RESULTS: Levels of weak, moderate, and strong DKK 1 expression were distributed - as 43.33, 27.78 and 25.56%, and 63.91, 18.80, and 1.50%, respectively when evaluating the samples obtained from the 1st and the 2nd group. Statistically significant differences were found when the levels of DKK 1 expression in the 1st and the 2nd group were compared (χ2 = 51; df = 3; p < 0.001).CONCLUSIONS: DKK 1 contributes to the development of osteolytic lesions in MM. The present study provides morphological evidence that inhibition in Wnt signaling may lead to bone damage observed in the advanced stage of the disease.

AB - BACKGROUND: Previous studies have pointed out the role of dickkopf-related protein 1 (DKK 1) - Wnt inhibitor, which is essential for osteoblast functioning, in the development of osteolytic lesions in multiple myeloma (MM).AIM: To assess the DKK 1 expression displayed by myeloma cells in bone marrow trephine biopsies of patients with and without osteolytic lesions, and in different malignancy grades of the disease.METHODS: The expression level of DKK 1 was assessed immunohistochemically in bone marrow of 49 MM patients presented with and without osteolytic lesions (the 1st and the 2nd group, respectively).RESULTS: Levels of weak, moderate, and strong DKK 1 expression were distributed - as 43.33, 27.78 and 25.56%, and 63.91, 18.80, and 1.50%, respectively when evaluating the samples obtained from the 1st and the 2nd group. Statistically significant differences were found when the levels of DKK 1 expression in the 1st and the 2nd group were compared (χ2 = 51; df = 3; p < 0.001).CONCLUSIONS: DKK 1 contributes to the development of osteolytic lesions in MM. The present study provides morphological evidence that inhibition in Wnt signaling may lead to bone damage observed in the advanced stage of the disease.

U2 - 10.32471/exp-oncology.2312-8852.vol-42-no-4.15289

DO - 10.32471/exp-oncology.2312-8852.vol-42-no-4.15289

M3 - Article

C2 - 33355872

SN - 1812-9269

VL - 42

SP - 285

EP - 288

JO - Experimental Oncology

JF - Experimental Oncology

IS - 4

ER -

Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type

Abstract

Field of Science*

Publication Type*

Access to Document

Fingerprint

Cite this